๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fuzhou
Clinical trial register · China

Clinical Trials in Fuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 63 Shanghai 52 Guangzhou 40 Hangzhou 19 Fuzhou 19
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing63 Shanghai52 Guangzhou40 Hangzhou19 Fuzhou19
All 68 locations
Target enrolment
to

Trials with a site in Fuzhou

19 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
NCT07414836Advanced Solid Tumor
BeOne Medicines
Phase 1
84
Beijing, Chongqing, Fuzhou, Guangzhou, Yichang, Shanghai
2026-04-13
Recruiting
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
NCT06953323Advanced Solid Tumor
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
86
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou
2025-07-10
Active, closed
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors
NCT06993116Advanced Solid Tumor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 1
15
Fuzhou, Changsha
2025-06-09
Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
NCT06825494Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
194
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Shenzhen, Nanning, Tangshan
2025-04-08
Recruiting
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
NCT06589596Advanced Solid Tumor
BeOne Medicines
Phase 1
525
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-01-10
Recruiting
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593Advanced Solid Tumor
BeOne Medicines
Phase 1
168
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin
2024-12-09
Recruiting
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
NCT06959615Advanced Solid Tumor
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
334
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Langfang, Haerbin, Zhengzhou
2024-11-22
Recruiting
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
NCT06598800Advanced Solid Tumor
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Recruiting
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
78
Beijing, Changsha, Fuzhou, Guangzhou, Shanghai
2024-09-04
Recruiting
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
NCT06487455Advanced Solid Tumor
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
170
Changsha, Fuzhou, Hangzhou, Kunming, Shanghai, Wuhan
2024-08-06
Recruiting
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
NCT06233942Advanced Solid Tumor
BeOne Medicines
Phase 1
308
Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan
2024-04-12
Recruiting
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
NCT06112704Advanced Solid Tumor
Hansoh BioMedical R&D Company
Phase 2
220
Hefei, Fujian, Fuzhou, Guangzhou, Harbin, Anyang, Luoyang, Nanyang
2024-02-06
Recruiting
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
NCT06253130Advanced Solid Tumor
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Active, closed
A Study YL201 in Patients With Selected Advanced Solid Tumors
NCT06057922Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
990
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou
2023-09-22
Recruiting
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
NCT06038396Advanced Solid Tumor
RemeGen Co., Ltd.
Phase 1/2
48
Fuzhou, Xiamen, Wuwei, Meizhou, Harbin, Nanyang, Xinyang, Zhengzhou
2023-08-03
Active, closed
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
NCT05744427Advanced Solid Tumor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Haโ€™erbin, Hefei, Jinan
2023-03-15
Active, closed
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329Advanced Solid Tumor
DualityBio Inc.
Phase 1/2
1,123
Bengbu, Hefei, Fuzhou, Lanzhou, Dongguan, Guangzhou, Guigang, Nanning
2022-07-19
Recruiting
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
NCT05170958Advanced Solid Tumor
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Rows per page Showing 1–19 of 19
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/fuzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 19 of those studies with a site in Fuzhou that also match the filters currently applied.

How many clinical trials are recruiting in Fuzhou?

15 of the 19 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Fuzhou), 19 studies
PhaseStudiesRecruitingShare
Phase 19847.4%
Phase 1/29647.4%
Phase 2115.3%

Most active sponsors

Lead sponsors with the most studies (Fuzhou)
Lead sponsorStudiesRecruiting
BeOne Medicines66
Axter Therapeutics (Beijing) Co., Ltd11
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.11
DualityBio Inc.10
Eikon Therapeutics11
Guangdong Hengrui Pharmaceutical Co., Ltd10
Hansoh BioMedical R&D Company11
Jacobio Pharmaceuticals Co., Ltd.11
Jiangsu Alphamab Biopharmaceuticals Co., Ltd10
MediLink Therapeutics (Suzhou) Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.